Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech disclosure the size of a clinical dossier is no small task. PTC Therapeutics’ filings stretch across hundreds of pages packed with trial data, royalty terms, and orphan-drug exclusivity clauses—details most investors cannot scan overnight. This page delivers PTC Therapeutics SEC filings explained simply so you can move from raw data to clear insight.
Stock Titan’s AI reads every submission the moment it hits EDGAR, translating jargon into plain language summaries. Whether you need a PTC Therapeutics quarterly earnings report 10-Q filing to track R&D burn, or an 8-K describing an FDA decision—PTC Therapeutics 8-K material events explained—our platform highlights the numbers and milestones that move the share price.
Key documents covered in real time:
- Form 4 – PTC Therapeutics insider trading Form 4 transactions and PTC Therapeutics Form 4 insider transactions real-time show exactly when executives buy or sell shares.
- 10-Q – AI pinpoints quarter-over-quarter pipeline spend, giving you fast PTC Therapeutics earnings report filing analysis.
- 10-K – Get the PTC Therapeutics annual report 10-K simplified, including cash-runway tables and risk-factor changes.
- DEF 14A – Review the PTC Therapeutics proxy statement executive compensation to evaluate incentives behind strategic decisions.
Still unsure where a specific disclosure lives? Type a plain question—“understanding PTC Therapeutics SEC documents with AI”—and let our engine surface the exact section, be it gene-therapy manufacturing obligations or collaboration milestones. Monitor PTC Therapeutics executive stock transactions Form 4, compare trial updates across periods, and make informed calls without wading through chemistry appendices. Complex science, distilled to actionable data—updated the second PTC files.
PTC Therapeutics, Inc. (PTCT) filed a Form 144 notice for a proposed sale of 12,000 common shares held at Fidelity Brokerage Services. The filing shows an aggregate market value of $700,128.81 and reports 79,438,094 shares outstanding, with an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired via an option granted on 01/04/2016 and are to be sold for cash; no sales in the prior three months were reported.
PTC Therapeutics Form 144 filing notifies a proposed sale of 39,850 common shares through Fidelity Brokerage Services with an aggregate market value of $2,268,373.83, intended for sale on 09/08/2025 on NASDAQ. The filing lists four lots acquired via stock options granted in 2016, 2017 and 2018 and shows cash payment on the stated sale date. The filing states there were no securities sold by the reporting person in the prior three months and includes the required attestation that the seller does not possess undisclosed material information. The notice follows Rule 144 disclosure requirements.
PTC Therapeutics insider sale disclosed: Director Allan Steven Jacobson reported a sale of 1,667 shares of PTC Therapeutics (PTCT) on 08/28/2025 at a price of $50.15 per share, reducing his beneficial ownership to 17,451 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing is a routine Section 16 disclosure showing an individual director executed a non-derivative sale.
PTC Therapeutics (PTCT) reported a proposed sale under Rule 144 of 1,667 shares of its common stock, with an aggregate market value of $83,601.72. The shares represent restricted stock that vested and were acquired on 06/17/2025 as compensation.
The filing names Fidelity Brokerage Services LLC as the broker and lists an approximate sale date of 08/28/2025 on the NASDAQ. The company’s total shares outstanding are reported as 79,438,094, making the proposed sale a very small fraction of outstanding stock.
PTC Therapeutics insider transactions on 08/15/2025 show Executive Vice President and CLO Mark Elliott Boulding exercised options to buy 2,813 shares at an exercise price of $25.69 and simultaneously sold 2,813 shares at a weighted average sale price of $48.58 per share under a Rule 10b5-1 plan. After the transactions, Mr. Boulding beneficially owned 103,901 shares of common stock and held 24,899 shares subject to unexercised options. The option was originally granted on February 14, 2024, vests over four years with an initial 25% vesting on February 15, 2025 and subsequent 6.25% quarterly vesting starting May 15, 2025. The Rule 10b5-1 plan was adopted December 5, 2024. The sale prices executed ranged from $48.24 to $49.11 and the filer offers to provide per-trade quantities upon request.
PTC Therapeutics (PTCT) filed a Form 144 notifying the proposed sale of 2,813 common shares held at Fidelity Brokerage Services, with an aggregate market value of $136,646.45, and an approximate sale date of 08/15/2025 on NASDAQ. The shares were acquired on 08/15/2025 via an option granted 02/15/2024 and payment will be in cash. The filing also lists two prior sales by the same person in May 2025 totaling 2,812 shares for gross proceeds of $129,715.92. The filer affirms no undisclosed material adverse information.
Armistice Capital and Steven Boyd report collective ownership of 4,735,464 shares of PTC Therapeutics common stock, representing 5.96% of the class. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager and exercises shared voting and dispositive power. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
On 5 Aug 2025, PTC Therapeutics (PTCT) entered a Rights Satisfaction Agreement with holders of roughly 90% of former Censa Pharmaceuticals equity. The deal cancels the royalty-style Net Sales Payments—8% on annual sepiapterin sales ≤ $250 M, 10% on sales > $250 M ≤ $500 M, and 12% on sales > $500 M—originally embedded in the 2020 Censa merger.
In exchange, PTC paid an up-front cash consideration of ≈ $225 M at closing and agreed to up to five additional milestone payments of ≈ $90 M each (aggregate ≈ $450 M) tied to cumulative global sepiapterin net-sales thresholds of $3 B, $5 B, $7 B, $9 B and $11 B achieved within rolling periods of 3–11 consecutive years. Any former Censa holder that later joins the agreement will receive its pro-rata share of the up-front and any future milestones.
The arrangement only affects the specified Net Sales Payments; all other contingent obligations under the original merger agreement remain intact. The agreement contained customary reps, warranties and covenants and closed simultaneously with signing.
FAQ
What is the current stock price of Ptc Therapeutics (PTCT)?
What is the market cap of Ptc Therapeutics (PTCT)?
